Redback Spider AntiVenom Evaluation (RAVE) Study

Phase 4

Completed

• Conditions: Redback spider envenoming; Other - Pain management

• Registration Number: ACTRN12605000146695
• Lead Sponsor: Geoff Isbister

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

(1) definite redback spider-bite and the spider is identified by the patient or clinician at the time of the bite; OR (2) clinical syndrome that is consistent with typical redback envenoming; AND the treating clinician would normally treat the patient with antivenom, namely: - moderate envenoming = severe local pain without systemic envenoming- severe envenoming = severe local pain and systemic features.

Exclusion Criteria

1. Patients who have received antivenom for this envenoming prior to enrolment2. Children aged <8 years 3. Bite occurring >24 hours ago

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinically important reduction in pain [2 hours after antivenom treatment]

Secondary Outcome Measures

Name	Time	Method
A clinically significant reduction in pain on the VAS on discharge.[Discharge time];Reduction in systemic symptoms and signs during ED admission.[By discharge time];Requirement for a third dose or further doses of antivenom.[By discharge time];Clinically significant change in VAS (or verbal analogue score where the VAS was not obtained).[At 24 hours.];Use of analgesics in the emergency department after commencing antivenom treatment.[By discharge time];Use of analgesics after discharge.[For up to 7 days]